Text Size

Intravitreal Bevacizumab for Diabetic Macular Edema

This study is enrolling participants by invitation only.
Sponsor:
Information provided by:
Isfahan Ophthalmology Research Center
ClinicalTrials.gov Identifier:
NCT00703235
First received: June 20, 2008
Last updated: NA
Last verified: June 2008
History: No changes posted
  Purpose

Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema.

This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.


Condition Intervention Phase
Macular Edema
Diabetic Retinopathy
 Drug: Bevacizumab
 Phase 2
Phase 3

Study Type: Interventional

Resource links provided by NLM:

Drug Information available for: Bevacizumab
U.S. FDA Resources

Further study details as provided by Isfahan Ophthalmology Research Center:

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diabetes mellitus
  • Clinically significant macular edema
  • Possibility of performing macular OCT
  • Consent of patient for inclusion in the study

Exclusion Criteria:

  • History of macular photocoagulation in less than 6 months of inclusion in the study
  • Necessity of surgical intervention
  • Rejection of the remaining in the study by patient
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00703235     History of Changes
Other Study ID Numbers: MUI - clinical - 185290
Study First Received: June 20, 2008
Last Updated: June 20, 2008
Health Authority: Iran: Ministry of Health

Additional relevant MeSH terms:
Diabetic Retinopathy
Edema
Macular Edema
Retinal Diseases
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Signs and Symptoms
 Macular Degeneration
Retinal Degeneration
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 16, 2013